Researchers from the Nanomol-bio group at ICMAB-CSIC have led the development of a innovative bimodal imaging probe for both magnetic resonance imaging (MRI) and fluorescence imaging. The study, conducted by Yufei Wu, Vega Lloveras, and Pepe Vidal from Nanomol-bio and other researchers, represents a significant step forward in biomedical imaging, offering a versatile tool for improved diagnostics and research applications.
The newly designed probe integrates a paramagnetic contrast agent for MRI with a fluorescent dye, enabling complementary imaging modalities in a single platform. This innovative approach allows for high-resolution anatomical imaging through MRI, while fluorescence imaging provides real-time visualization at the cellular level. The combination of both techniques enhances accuracy in medical imaging and facilitates a deeper understanding of biological processes.
One of the key advantages of this new probe is its water solubility and biocompatibility, making it a promising candidate for future biomedical applications. The study demonstrates its effectiveness in both in vitro and in vivo models, showing its potential for non-invasive imaging in medical diagnostics and research.
The research, published in ACS Applied Materials and interfaces (Wu, Y., Lloveras, V., Vidal‐Gancedo, J., et col., 2024), is the result of a collaborative effort between ICMAB-CSIC, CIBER-BBN, and national and international partners. It highlights the expertise of Nanomol-bio scientists in the development of advanced nanomaterials for healthcare applications, rthus reinforcing its role in diagnostic biomedical research.
With this breakthrough, the Nanomol-bio team continues to push the boundaries of nanomedicine and medical imaging. Their work opens new possibilities for more precise and efficient diagnostic tools, which could ultimately improve patient outcomes and advance the field of biomedical imaging.
